Zentiva’s Climate Goals Receive Validation from Science Based Targets initiative (SBTi)
PRAGUE, Czech Republic – July 14, 2025 – Zentiva, a leading European pharmaceutical company, is proud to announce that its ambitious climate targets have been officially validated by the Science Based Targets initiative (SBTi). This significant endorsement underscores Zentiva’s commitment to contributing to a more sustainable future and aligns its environmental efforts with the most up-to-date climate science.
The SBTi is a globally recognized organization that empowers companies to set ambitious, science-based emissions reduction targets in line with the goals of the Paris Agreement. By having its targets validated, Zentiva demonstrates a clear pathway to significantly reduce its greenhouse gas emissions across its entire value chain, both in the short and long term.
This validation is a testament to Zentiva’s dedication to corporate responsibility and its understanding of the critical role businesses play in addressing the climate crisis. The company has meticulously developed its climate strategy, incorporating emissions reductions from its own operations (Scope 1 and 2) as well as those generated by its supply chain and the use of its products (Scope 3).
“We are delighted to receive this validation from the SBTi, which reinforces our unwavering commitment to environmental sustainability,” said [Name and Title of relevant Zentiva executive, e.g., CEO or Chief Sustainability Officer]. “At Zentiva, we believe that responsible business practices are not only essential for the planet but also for the long-term success of our company and the well-being of the communities we serve. Achieving SBTi validation is a crucial step in our journey to minimize our environmental footprint and contribute to a low-carbon economy.”
The SBTi validation process involves a rigorous review of a company’s emissions reduction targets to ensure they are consistent with the level of decarbonization required to keep global warming below 1.5°C. Zentiva’s validated targets reflect a comprehensive approach to emission reduction, demonstrating a proactive stance in mitigating its climate impact.
As a pharmaceutical company, Zentiva recognizes the importance of a healthy planet for public health. By setting and achieving science-based targets, Zentiva aims to not only reduce its environmental impact but also to inspire other organizations within the healthcare sector and beyond to embrace similar ambitious climate action.
This achievement highlights Zentiva’s ongoing commitment to transparency and accountability in its sustainability efforts. The company will continue to monitor its progress, innovate in its operations, and collaborate with stakeholders to drive meaningful change towards a more sustainable future.
About Zentiva
Zentiva is a leading European pharmaceutical company dedicated to providing high-quality, affordable medicines that meet people’s everyday healthcare needs. With a strong presence in Europe and beyond, Zentiva offers a broad portfolio of prescription and over-the-counter medicines, as well as consumer healthcare products. The company is committed to making healthcare more accessible and sustainable for patients and healthcare systems alike.
About the Science Based Targets initiative (SBTi)
The Science Based Targets initiative (SBTi) is a collaboration between CDP, the United Nations Global Compact, We Mean Business coalition, and the World Resources Institute (WRI). The SBTi defines and promotes best practices in emissions reductions and net-zero targets in line with climate science. It also provides resources and guidance to help companies set and measure their targets.
Los objetivos climáticos de Zentiva fueron validados por la Iniciativa Science Based Targets (SBTi)
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
www.prnewswire.com published ‘Los objetivos climáticos de Zentiva fueron validados por la Iniciativa Science Based Targets (SBTi)’ at 2025-07-14 09:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.